FDA Approves Centanafadine for ADHD - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves Centanafadine for ADHD

The first approved norepinephrine, dopamine, and serotonin reuptake inhibitor for ADHD demonstrated symptom improvements as early as week 1 in phase 3 trials.

  • By

  • Kathryn Wighton

  • July 27, 2026

  • 3 min

Share

Original Source(s)

FDA Approves Centanafadine for ADHD

  • by Kathryn Wighton

  • July 27, 2026

Related Content

Dual-Site Theta Burst Stimulation May Reduce Suicidal Ideation

Four-day treatment targeting the prefrontal cortex and cerebellum produced larger reductions in suicidal ideation scores than prefrontal stimulation alone in adolescents with major depressive disorder.

Associations of mobile internet use and depressive symptoms with cognitive performance among Chinese adolescents: a cross-sectional study

Thyroid-stimulating hormone, fasting blood glucose and suicidal ideation in Chinese adolescents with major depressive disorder: a cross-sectional study